Literature DB >> 22573858

Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection.

Mary E Miller1, Shramika Adhikary, Andrey A Kolokoltsov, Robert A Davey.   

Abstract

Acid sphingomyelinase (ASMase) converts the lipid sphingomyelin (SM) to phosphocholine and ceramide and has optimum activity at acidic pH. Normally, ASMase is located in lysosomes and endosomes, but membrane damage or the interaction with some bacterial and viral pathogens can trigger its recruitment to the plasma membrane. Rhinovirus and measles viruses each require ASMase activity during early stages of infection. Both sphingomyelin and ceramide are important components of lipid rafts and are potent signaling molecules. Each plays roles in mediating macropinocytosis, which has been shown to be important for ebolavirus (EBOV) infection. Here, we investigated the role of ASMase and its substrate, SM, in EBOV infection. The work was performed at biosafety level 4 with wild-type virus with specificity and mechanistic analysis performed using virus pseudotypes and virus-like particles. We found that virus particles strongly associate with the SM-rich regions of the cell membrane and depletion of SM reduces EBOV infection. ASM-specific drugs and multiple small interfering RNAs strongly inhibit the infection by EBOV and EBOV glycoprotein pseudotyped viruses but not by the pseudotypes bearing the glycoprotein of vesicular stomatitis virus. Interestingly, the binding of virus-like particles to cells is strongly associated with surface-localized ASMase as well as SM-enriched sites. Our work suggests that ASMase activity and SM presence are necessary for efficient infection of cells by EBOV. The inhibition of this pathway may provide new avenues for drug treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22573858      PMCID: PMC3416309          DOI: 10.1128/JVI.00136-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Macropinocytosis as a mechanism of entry into primary human urethral epithelial cells by Neisseria gonorrhoeae.

Authors:  M K Zenni; P C Giardina; H A Harvey; J Shao; M R Ketterer; D M Lubaroff; R D Williams; M A Apicella
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

Review 2.  Acid sphingomyelinase-derived ceramide signaling in apoptosis.

Authors:  Erich Gulbins; Richard Kolesnick
Journal:  Subcell Biochem       Date:  2002

3.  Acid sphingomyelinase is involved in CEACAM receptor-mediated phagocytosis of Neisseria gonorrhoeae.

Authors:  C R Hauck; H Grassmé; J Bock; V Jendrossek; K Ferlinz; T F Meyer; E Gulbins
Journal:  FEBS Lett       Date:  2000-08-04       Impact factor: 4.124

4.  C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans.

Authors:  Carmen P Alvarez; Fátima Lasala; Jaime Carrillo; Oscar Muñiz; Angel L Corbí; Rafael Delgado
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 5.  The acid sphingomyelinase/ceramide pathway: biomedical significance and mechanisms of regulation.

Authors:  Y H Zeidan; Y A Hannun
Journal:  Curr Mol Med       Date:  2010-07       Impact factor: 2.222

6.  Neisseria gonorrhoeae porin P1.B induces endosome exocytosis and a redistribution of Lamp1 to the plasma membrane.

Authors:  Patricia Ayala; Brandi Vasquez; Lee Wetzler; Magdalene So
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

7.  Association of the caveola vesicular system with cellular entry by filoviruses.

Authors:  Cyril J Empig; Mark A Goldsmith
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

8.  Sindbis virus entry into cells triggers apoptosis by activating sphingomyelinase, leading to the release of ceramide.

Authors:  J T Jan; S Chatterjee; D E Griffin
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 9.  Acid and neutral sphingomyelinases: roles and mechanisms of regulation.

Authors:  Norma Marchesini; Yusuf A Hannun
Journal:  Biochem Cell Biol       Date:  2004-02       Impact factor: 3.626

10.  Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses.

Authors:  Sina Bavari; Catharine M Bosio; Elizabeth Wiegand; Gordon Ruthel; Amy B Will; Thomas W Geisbert; Michael Hevey; Connie Schmaljohn; Alan Schmaljohn; M Javad Aman
Journal:  J Exp Med       Date:  2002-03-04       Impact factor: 14.307

View more
  56 in total

1.  Switching head group selectivity in mammalian sphingolipid biosynthesis by active-site engineering of sphingomyelin synthases.

Authors:  Matthijs Kol; Radhakrishnan Panatala; Mirjana Nordmann; Leoni Swart; Leonie van Suijlekom; Birol Cabukusta; Angelika Hilderink; Tanja Grabietz; John G M Mina; Pentti Somerharju; Sergei Korneev; Fikadu G Tafesse; Joost C M Holthuis
Journal:  J Lipid Res       Date:  2016-05-10       Impact factor: 5.922

2.  Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors.

Authors:  Manu Anantpadma; Jennifer Kouznetsova; Hang Wang; Ruili Huang; Andrey Kolokoltsov; Rajarshi Guha; Aaron R Lindstrom; Olena Shtanko; Anton Simeonov; David J Maloney; Wendy Maury; Douglas J LaCount; Ajit Jadhav; Robert A Davey
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

3.  Altered Clathrin-Independent Endocytosis in Type A Niemann-Pick Disease Cells and Rescue by ICAM-1-Targeted Enzyme Delivery.

Authors:  Jeff Rappaport; Rachel L Manthe; Carmen Garnacho; Silvia Muro
Journal:  Mol Pharm       Date:  2015-04-23       Impact factor: 4.939

4.  Transmembrane Domain Dissociation Is Required for Hendra Virus F Protein Fusogenic Activity.

Authors:  Kerri Beth Slaughter; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

5.  Synergistic drug combination effectively blocks Ebola virus infection.

Authors:  Wei Sun; Shihua He; Carles Martínez-Romero; Jennifer Kouznetsova; Gregory Tawa; Miao Xu; Paul Shinn; Ethan Fisher; Yan Long; Omid Motabar; Shu Yang; Philip E Sanderson; Peter R Williamson; Adolfo García-Sastre; Xiangguo Qiu; Wei Zheng
Journal:  Antiviral Res       Date:  2016-11-24       Impact factor: 5.970

6.  Switching head group selectivity in mammalian sphingolipid biosynthesis by active-site-engineering of sphingomyelin synthases.

Authors:  Matthijs Kol; Radhakrishnan Panatala; Mirjana Nordmann; Leoni Swart; Leonie van Suijlekom; Birol Cabukusta; Angelika Hilderink; Tanja Grabietz; John G M Mina; Pentti Somerharju; Sergei Korneev; Fikadu G Tafesse; Joost C M Holthuis
Journal:  J Lipid Res       Date:  2017-03-23       Impact factor: 5.922

7.  Repurposing potential of 1st generation H1-specific antihistamines as anti-filovirus therapeutics.

Authors:  Adam Schafer; Han Cheng; Rui Xiong; Veronica Soloveva; Cary Retterer; Feiyan Mo; Sina Bavari; Gregory Thatcher; Lijun Rong
Journal:  Antiviral Res       Date:  2018-07-04       Impact factor: 5.970

8.  Sphingomyelin Is Essential for the Structure and Function of the Double-Membrane Vesicles in Hepatitis C Virus RNA Replication Factories.

Authors:  Hossam Gewaid; Haruyo Aoyagi; Minetaro Arita; Koichi Watashi; Ryosuke Suzuki; Shota Sakai; Keigo Kumagai; Toshiyuki Yamaji; Masayoshi Fukasawa; Fumihiro Kato; Takayuki Hishiki; Ayako Mimata; Yuriko Sakamaki; Shizuko Ichinose; Kentaro Hanada; Masamichi Muramatsu; Takaji Wakita; Hideki Aizaki
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

9.  Acid Sphingomyelinase Promotes Endothelial Stress Response in Systemic Inflammation and Sepsis.

Authors:  Ha-Yeun Chung; Daniel C Hupe; Gordon P Otto; Marcel Sprenger; Alexander C Bunck; Michael J Dorer; Clemens L Bockmeyer; Hans-Peter Deigner; Markus H Gräler; Ralf A Claus
Journal:  Mol Med       Date:  2016-06-15       Impact factor: 6.354

10.  Analysis of Lujo virus cell entry using pseudotype vesicular stomatitis virus.

Authors:  Hideki Tani; Koichiro Iha; Masayuki Shimojima; Shuetsu Fukushi; Satoshi Taniguchi; Tomoki Yoshikawa; Yoshihiro Kawaoka; Naoe Nakasone; Haruaki Ninomiya; Masayuki Saijo; Shigeru Morikawa
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.